WO1994008709A1 - Production method for fine granulate - Google Patents
Production method for fine granulate Download PDFInfo
- Publication number
- WO1994008709A1 WO1994008709A1 PCT/JP1993/001442 JP9301442W WO9408709A1 WO 1994008709 A1 WO1994008709 A1 WO 1994008709A1 JP 9301442 W JP9301442 W JP 9301442W WO 9408709 A1 WO9408709 A1 WO 9408709A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fine
- granulation
- binder
- particles
- surfactant
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/16—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by suspending the powder material in a gas, e.g. in fluidised beds or as a falling curtain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/10—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/12—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in rotating drums
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Definitions
- the present invention relates to a method for producing fine granules. More specifically, in the case of pharmaceuticals, it is suitable for the production of poorly soluble or poorly absorbable drugs and pharmaceutical preparations that require a high content of the main drug, and also in the fields of food and fertilizers.
- the present invention relates to a method for producing a fine granule capable of providing a fine granule having good usability as a powder. Background art
- the active ingredient (drug) in the solid dosage form is released from the preparation in the gastrointestinal tract, elutes into body fluids, is absorbed, enters the systemic blood, and exerts its medicinal effects.
- drug drug
- particularly poorly soluble drugs have low dissolution properties, and may be excreted outside the body before all of the administered drug is dissolved, thus failing to exert sufficient drug efficacy.
- Various methods have been studied to date for improving the dissolution of poorly soluble drugs. For example, a method of co-pulverizing a poorly soluble drug with / S-1,4 glucan powder (Japanese Patent Publication No.
- an excessively fine powder generally has a problem in that it is inferior in operability in formulation and filling and packaging due to reduced fluidity and scattering. Therefore, for example, capsule filling cannot be performed as it is, and it is general to add a fluidizing agent as a secondary formulation to enhance capsule filling. Therefore, for example, a drug whose drug content requires a relatively high dose due to a drastic decrease in the content of the main drug, poor solubility, poor absorption, etc., or a drug that requires a clinically high dose such as an antibiotic In such a case, the use of the capsule may become inconvenient, for example, the capsule size may become large or a plurality of capsules must be taken at one time.
- formulation is usually designed by granulation, tableting, etc. after pulverization
- various additives are added for the purpose of expecting the disintegration of the formulation, dissolution of the drug, dispersibility, absorption, etc.
- drugs requiring a high dose often cause inconvenience in use for patients for the same reasons as described above.
- fine granulation with as high an active substance content as possible is desired.
- fine granulation techniques such as dry coating granulation using equipment such as a high-speed rotary mixer, solid dispersion granulation, fluidized drying granulation, spray drying granulation, and wet granulation.
- the present inventors have conducted research on a method for solving the above-mentioned problem, and as a result, after pulverizing a poorly soluble medicinal ingredient as a target compound by selecting an appropriate carrier and co-milling the same, By repeating the process of spraying and granulating an aqueous solution in which a water-soluble polymer is dissolved or an aqueous solution further containing a surfactant by means of a jet nozzle or the like, a sharp particle size distribution is obtained. It has been found that fine granules having a good flowability of 0.2 mm or less can be obtained with good productivity, and that the finely powdered granules can be obtained before, during, or after granulation. Of finer particles such as highly dispersible The present inventors have found that a granule having the same effect can be obtained by additionally using a step of mixing and stirring as a mobilizing agent to perform surface processing, thereby completing the present invention.
- the gist of the present invention is:
- FIG. 1 is a photograph showing the particle structure of a drug substance (micronized product) by SEM scanning electron microscopy (magnification: 500 times).
- FIG. 2 is a photograph showing the particle structure of the fine granules of Example 2 by SEM scanning electron microscope observation (magnification: 500 times).
- FIG. 3 is a photograph showing the particle structure of the fine granules of Example 2 obtained by SEM scanning electron microscope observation (enlarged 1500 times).
- FIG. 4 is a photograph showing the particle structure of the fine granules of Example 2 by SEM scanning electron microscope observation (3500 times magnification).
- FIG. 5 is a photograph showing the particle structure of the fine granules of Example 3 by SEM scanning electron microscope observation (100 times magnification).
- FIG. 6 is a photograph showing the particle structure of the fine granules of Example 3 observed by SEM scanning type electric head observation (magnification: 500 times).
- FIG. 7 is a photograph showing the particle structure of the fine granules of Example 3 obtained by SEM scanning electron microscope observation (magnification: 2000 times).
- Figure 8 shows the particle size distribution of the drug substance (micronized product), the fine granulated product of Example 2 (10% granulated product), and the fine granulated product of Example 3 (15% granulated product).
- FIG. 7 is a photograph showing the particle structure of the fine granules of Example 3 obtained by SEM scanning electron microscope observation (magnification: 2000 times).
- Figure 8 shows the particle size distribution of the drug substance (micronized product), the fine granulated product of Example 2 (10% granulated product), and the fine granulated product of Example 3 (15% granulated product).
- Figure 9 shows the area under blood concentration (AUC) when the fine granules of Example 3 were administered to beagle dogs in comparison with various controls.
- the pulverized powder having an average particle size of 1 or less is usually obtained by co-pulverizing the compound of interest with a carrier.
- a carrier is not limited at all, and usually the most effective carrier is selected from talc, calcium hydrogen phosphate, silicic acid anhydride, crystalline cellulose, lactose, mannitol and the like. It is effective to use a crusher such as a jet mill or a hammer mill as the device used for crushing. Thereby, it is usually pulverized to 10 or less.
- a carrier is not necessarily required depending on the raw material.
- the compound to be subjected to fine granules in the present invention varies depending on the application field of the present invention, and is not particularly limited.
- the field include poorly soluble and Z or poorly absorbable medicinal ingredients.
- the poorly soluble and / or poorly absorbable medicinal component is subject to any requirement for some form of formulation because the solubility or absorbability is low as it is, and the degree of solubility or absorbability is considered. Is not particularly limited.
- solubility among various drugs such as antibacterial substances, antiviral agents, cardiovascular drugs, immunomodulators, anticancer drugs, and anti-inflammatory drugs. Because of low absorption, any drug that needs to increase solubility and absorption can be applied. In the fields of food, fertilizer, etc., they are also targeted according to various purposes.
- an antibacterial substance represented by KRM-1648 in the Examples is exemplified.
- the binder is preferably a water-soluble polymer, and among them, a binder having a low molecular weight and a low viscosity is preferable because of its weak bonding force, and gives good physical properties for fine granulation.
- a binder having a low molecular weight and a low viscosity is preferable because of its weak bonding force, and gives good physical properties for fine granulation.
- the higher the molecular weight of a water-soluble polymer the higher the viscosity and the stronger the binding force, and the higher the gelation, which causes inconvenience in operability and makes it difficult to obtain fine granules.
- a water-soluble polymer such as hydroxypropyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, or polyvinylpyrrolidone is used.
- those having a low viscosity as described above are preferable, and those having a not too strong binding force are preferably used because the granules are easily controlled.
- HPC-SL and HPC-SSL manufactured by Nippon Soda Co., Ltd. may be mentioned, and HPC-SSL grade is particularly preferable.
- the binder one or two kinds of the above water-soluble polymers are used. Used in combination above.
- starch glue, carmellose, tragacanth, gum arabic, sodium alginate, etc. which can be generally used as a binder without being a water-soluble polymer as described above, may be used. It can be used for the above purpose by appropriately adjusting the amount. The amount of such a general binder used in combination varies depending on the equipment used, and is appropriately adjusted.
- the viscosity increases, the binding force increases, and the gel is formed, which is preferable in terms of operability and physical properties given to the particles during granulation (for example, uniform coating on the particle surface). Absent. However, as a method to overcome this, the viscosity can be reduced by the coexistence of a surfactant.
- the surfactant used is not limited at all.
- the addition of the surfactant reduces the viscosity of the binder or wets the water during granulation. It is sufficient if it has a function of improving the water content and preventing the occurrence of "occassion", but a hydrophilic surfactant is preferable in order to further improve the wetting with water.
- hydrophilic sucrose fatty acid esters, polyoxyl stearate, polyethylene glycol, polysorbate or polyoxyethylene polyoxypropylene glycol are preferred.
- the granulation of the fine powder is promoted in the presence of a binder such as a water-soluble polymer, or in the presence of the binder and a surfactant.
- a binder such as a water-soluble polymer
- a surfactant Combined with the surface processing performed in this way, it is possible to achieve fine granulation with a very uniform particle size.
- the surface of the agitated, tumbled, or fluidized pulverized material is required.
- the surfactant and the water-soluble polymer may be sprayed from each nozzle, or a mixture of both may be sprayed.
- the usage of the surfactant is usually 10% by weight or less based on the finely powdered substance, and the usage of the water-soluble polymer is usually 1 to 20% by weight based on the finely powdered substance.
- the surface treatment performed by mixing and stirring particles having a fine particle diameter is finer than the pulverized powder, and can be performed by, for example, high-speed dry mixing.
- the fine particle diameter particles adhere to the surface of the pulverized product, or the fine particle diameter particles are deposited near the surface. Can coexist.
- such a state that the surface of the pulverized material or the vicinity of the surface is in a state in which particles having a fine particle size coexist is referred to as surface processing.
- the particles having a fine particle diameter highly dispersible silica of light anhydrous silicic acid (Aerosil, manufactured by Nippon Aerosil Industry Co., Ltd.) is preferably used.
- AEROSIL # 200 manufactured by Nippon AEROSIL KOGYO CO., LTD. Is a particle having a specific surface area of 200 m 2 and an average particle diameter of 12 nm.
- the surface treatment with fine particles is carried out, for example, before the granulation step, or in the granulation process, or after the completion of the granulation.
- Fine grain There is no particular limitation on the timing and the number of times the surface processing is performed using particles having a diameter, and it is appropriately performed before, during, and after the above-described granulation. For example, it is performed by alternately repeating such a surface processing and a granulating step. In this case, the number of repetitions varies depending on the type and amount of the pulverized product, binder, surfactant and the like, and the particle size of the target granulated product, and is appropriately selected. Such a method of alternately repeating is preferable in that the coating is performed uniformly and a heavy material is obtained.
- the influence on the granulation itself and the fluidity of the fine granules obtained by granulation are obtained. It has a useful effect for improvement.
- the amount of the fine particles used here is usually 1 to 5% by weight with respect to the fine powder.
- other components such as an absorption promoter and a stabilizer can be appropriately used in combination.
- Such other components are not particularly limited, and are appropriately selected and used depending on the compound to be granulated.
- an absorption enhancer may be used in combination.
- a compound of interest may be compounded when co-grinding with a carrier or when performing surface processing using fine particles, or a surfactant and It may be blended when granulating in the presence of a binder such as a water-soluble polymer, and is not particularly limited.
- an apparatus that can be used for performing the step of mixing and stirring fine particles having a fine particle diameter and the step of performing fine granulation with the same apparatus includes, in addition to a general fluidized bed granulation coating function, Those that require the functions of the composite type shown below are appropriate.
- Worster-fluidized bed granulation Coating equipment for example, Grat Co., Ltd. or Baurek Co., Ltd.
- a worst-power column on a cylinder is installed in the center of the vessel, and particles of the pulverized material and granulated material are placed in an updraft (jet) and flow in a unidirectional flow.
- the target particles are sprayed upward from the bottom jet nozzle (bottom spray one-way) to spray, coat, granulate and dry fine droplets consisting of a binder or a binder and a surfactant.
- a granulating coating device with a stirring-rolling fluidized bed-type composite function for example, Spirah Mouth-Granulating Coating Device manufactured by Freund Corporation
- a granulating coater having a composite function of a rolling fluidized bed type for example, a multiplex manufactured by Baurec Co., Ltd.
- Spraying methods of the granulating coating equipment having these combined functions include a top spray method from the top, a middle spray (evening spray) method on the bottom side, and a bottom spray method.
- a middle spray (tangential) method or a bottom spray method from the bottom side is effective for fine granulation.
- the binder that collides with the pulverized product or the granulated product, and the particle size of the droplet particles composed of the surfactant are made as small as possible, and the particles collide with the target particles. It is necessary to increase the speed to prevent the flocculation (agglomeration) during the granulation process and to combine the uniformly coated particles to control the particles into fine granules.
- the concentration and amount of fine particles, hydrophilic surfactants, binders, etc. used in such surface processing and granulation are determined by the granulation obtained. It can be appropriately selected according to the equipment to be used so that the body has a desired particle size of 0.2 mm or less.
- the particle size means a value measured by SEM scanning electron microscope observation or sieving.
- the granules obtained in this way have a particle size distribution of less than 0.2 mm, preferably less than 0.1 mm, with an extremely sharp fluidity and improved wetting with water. .
- the granules of the present invention are not granulated by adding an excipient, they have a high content of the main drug and are advantageous as a pharmaceutical preparation requiring a high dose as described above, and also have improved absorption. Can be expected.
- the content of the micronized product in the granulated product is at least 80%, and the content of the medicinal component is at least 60%, preferably at least 70%.
- this can be tableted by a general method. It can also be used in fields such as food and fertilizer, as well as pharmaceuticals.
- KRM-164 8 (C 51 H 64 N 40 is; MW 941.), which is being researched and developed by Kaneka Chemical Industry Co., Ltd., as a model of a poorly soluble and poorly absorbable drug. 0 9) was used.
- KRM-1648 is a hardly soluble antibacterial substance that hardly dissolves in water, and is colored deep purple. It is a compound in which operability such as scattering property becomes a problem.
- K RM-1 648 is an abbreviation for 3,4-hydroxyl 5 '-[4-isobutyl-1-piperazinyl] -benzobenzoxazino rifamycin, which is a derivative of rifamycin S. against infectious atypical mycobacteria such as avium complex, Mycobacterium tuberculosis, etc. It has a strong antibacterial effect on the body and is an antibacterial agent that prevents opportunistic infections when immunity is reduced.
- AEROSIL # 200 (manufactured by Nippon AEROSIL INDUSTRY CO., LTD.) was added to 250 g of the raw material of the finely powdered product, and 5 g of a Wurster fluidized bed granulation coating device (manufactured by Glatt Co., Ltd., Glatt GPCG-1 Wurster), and mixed at high speed in a fluidized tank. Then, aerosil # 200 is adhered to the surface of the drug substance raw material powder to perform surface treatment.
- DK ester F-160 of sucrose fatty acid ester (manufactured by Dai-ichi Kogyo Seiyaku Co., Ltd.)
- Water-soluble polymer hydroxypropylcellulose HPC-SSL (manufactured by Nippon Soda Co., Ltd.) was mixed with an aqueous solution having a concentration of 0.05% and 5%, respectively.
- Granulation was performed by spray addition.
- HPC-SSL was added in an amount of 5% based on the base drug K RM-1 648 and spraying was stopped at the stage of granulation, and 4 g of the above Aerosil # 200 was added.
- the particles were surface-treated by high-speed fluidized stirring and mixing in the drying process, and fine particles of about 20 m or less in the middle of granulation were obtained by SEM scanning electron microscope observation.
- Example 2 The particles in the middle of granulation obtained in Example 1 were charged into a Wurster-fluidized bed granulation coating device (Glatt Co., Ltd., Glatt GPCG-1 Wurster), and the above-mentioned sucrose fatty acid ester DK ester F—16 was added.
- 0 manufactured by Daiichi Kogyo Seiyaku Co., Ltd.
- water-soluble high molecular weight hydroxyl propyl cellulose HPC-SSL manufactured by Nippon Soda Co., Ltd.
- Example 3 Sprayed with a jet nozzle in the form of a jet to add HPC-SSL in an amount of 10% with respect to the main drug KRM-1684, granulated, and then aerosil # 20 in the drying process 0 (manufactured by Nippon Aerosil Industry Co., Ltd.) 2 g was added, and the particles were subjected to surface treatment by high-speed fluidized stirring and mixing in the same apparatus to form fine granules (particle size was reduced by SEM scanning electron microscope observation). 20 to 40 urn). The content of the pulverized product in the granulated product was 87%, and the content of KRM-1648 was 70%.
- Example 3 Sprayed with a jet nozzle in the form of a jet to add HPC-SSL in an amount of 10% with respect to the main drug KRM-1684, granulated, and then aerosil # 20 in the drying process 0 (manufactured by Nippon Aerosil Industry Co., Ltd.) 2 g was added, and
- Example 2 Wurster-fluidized bed granulation coating of the fine granules obtained in Example 2 DK ester F-160 (manufactured by Dai-ichi Kogyo Seiyaku Co., Ltd.) and water-soluble polymer
- AEROSIL # 200 manufactured by Nippon AEROSIL KOGYO CO., LTD.
- the particles were subjected to surface treatment by high-speed fluidized stirring and mixing to obtain fine granules (particle size of about 50 to 70 ⁇ m by SEM scanning electron microscope observation).
- the content of the finely powdered product in the granulated product was 82%, and the content of KRM-1648 was 66%.
- Aerosil # 200 manufactured by Nippon Aerosil Co., Ltd.
- (16 g) was added to 800 g of the raw material of the pulverized product for the formulation, and the fluidized bed granulation coating device (Front) was used.
- FIGS. 5 to 7 show the observations (100, 5) of the fine granules of Example 3 (abbreviated as 15% granules). 5 to 7 are shown in FIGS. 5 to 7. As is clear from FIGS.
- the particle size of the drug substance (pulverized product) is about 5 to 10 zm, but the fine granulated product of Example 2 is about 20 to 40 m.
- the fine granules of Example 3 had a particle size of about 50 to 70 / m.
- Figure 8 shows the results of the particle size distribution based on the volume occupied by the particle size.
- the device is PIA's image breaking device PIA Type S III.
- the method of the present invention produces a fine granulated product having an average particle size of 70 to 80 m and a particle size distribution of 0.2 mm or less and having a very sharp particle size distribution. It is suggested that it can be obtained
- the granulation method of the present invention provides a method for producing a fine granule having a very uniform particle size of 0.2 mm or less from a finely powdered product.
- a pharmaceutical preparation that requires a high content of a poorly soluble or poorly absorbable drug component and a main drug.
- fine granules having good usability in the fields of food and fertilizer can be provided as powder.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- General Preparation And Processing Of Foods (AREA)
- Fertilizers (AREA)
- Glanulating (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP50982594A JP3492688B2 (ja) | 1992-10-09 | 1993-10-06 | 微細な造粒体の製造方法 |
DE69322764T DE69322764T2 (de) | 1992-10-09 | 1993-10-06 | Herstellungsmethode für feines granulat |
US08/244,375 US5547683A (en) | 1992-10-09 | 1993-10-06 | Method for producing microgranulated particle |
CA002124568A CA2124568C (en) | 1992-10-09 | 1993-10-06 | Method for producing microgranulated particle |
KR1019940701971A KR100294525B1 (ko) | 1992-10-09 | 1993-10-06 | 미세한조립체의제조방법 |
EP93922047A EP0616841B1 (en) | 1992-10-09 | 1993-10-06 | Production method for fine granulate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29790592 | 1992-10-09 | ||
JP4/297905 | 1992-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994008709A1 true WO1994008709A1 (en) | 1994-04-28 |
Family
ID=17852618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/001442 WO1994008709A1 (en) | 1992-10-09 | 1993-10-06 | Production method for fine granulate |
Country Status (9)
Country | Link |
---|---|
US (1) | US5547683A (ja) |
EP (1) | EP0616841B1 (ja) |
JP (1) | JP3492688B2 (ja) |
KR (1) | KR100294525B1 (ja) |
CN (1) | CN1089234C (ja) |
CA (1) | CA2124568C (ja) |
DE (1) | DE69322764T2 (ja) |
ES (1) | ES2124794T3 (ja) |
WO (1) | WO1994008709A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001509518A (ja) * | 1997-07-09 | 2001-07-24 | エラン ファーマシューティカル テクノロジーズ | セルロース系表面安定剤を用いたヒト免疫不全ウイルス(hiv)プロテアーゼ阻害剤のナノ結晶製剤及びそのような製剤の製造方法 |
JP2003001091A (ja) * | 2001-06-26 | 2003-01-07 | Pauretsuku:Kk | 流動層造粒・コーティング方法 |
WO2004078212A1 (ja) * | 2003-03-06 | 2004-09-16 | Yamanouchi Pharmaceutical Co., Ltd. | 放出制御用医薬組成物およびその製造方法 |
WO2005065715A1 (ja) * | 2003-12-25 | 2005-07-21 | Takeda Pharmaceutical Company Limited | 造粒性改善方法 |
JP2007246539A (ja) * | 1997-10-20 | 2007-09-27 | Dainippon Sumitomo Pharma Co Ltd | 速溶性医薬組成物 |
JP2007528865A (ja) * | 2003-07-17 | 2007-10-18 | エチファルム | 共沈活性物質含有粒子 |
WO2007126063A1 (ja) * | 2006-04-28 | 2007-11-08 | Lion Corporation | 造粒粒子、錠剤、及び造粒粒子の製造方法 |
JP2007314529A (ja) * | 2006-04-28 | 2007-12-06 | Lion Corp | 造粒粒子、錠剤、及び造粒粒子の製造方法 |
JP2009019057A (ja) * | 1996-03-26 | 2009-01-29 | Eli Lilly & Co | ベンゾチオフェン類、それを含む製剤、および方法 |
JP2010280707A (ja) * | 2003-07-11 | 2010-12-16 | F Hoffmann La Roche Ag | メシル酸サキナビル経口投与剤型 |
WO2011125500A1 (ja) * | 2010-03-31 | 2011-10-13 | エスエス製薬株式会社 | 難水溶性薬物含有微粒子造粒物の製造法 |
JP2021075492A (ja) * | 2019-11-11 | 2021-05-20 | 花王株式会社 | 造粒物の製造方法 |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2259298A1 (en) * | 1996-07-01 | 1998-01-08 | Pfizer Inc. | Virginiamycin mixture |
ES2129010B1 (es) * | 1997-01-02 | 2000-01-16 | Gold Oscar | Composicion de accion prolongada en granulos que contienen 4-nitro-2- fenoximetansulfonanilida y su procedimiento de preparacion. |
FR2760190B1 (fr) * | 1997-02-28 | 1999-04-09 | Adir | Composition pharmaceutique pour la liberation programmee de dexfenfluramine |
US6013280A (en) * | 1997-10-07 | 2000-01-11 | Fuisz Technologies Ltd. | Immediate release dosage forms containing microspheres |
JP2000128774A (ja) | 1998-10-26 | 2000-05-09 | Tanabe Seiyaku Co Ltd | 薬物を含有する球形微粒子の製法 |
FR2791905B1 (fr) * | 1999-04-09 | 2001-09-14 | Toulouse Inst Nat Polytech | Procede d'enrobage et de pelliculage de poudres fines dans un enrobeur a lit fluidise |
US6417227B1 (en) | 1999-04-28 | 2002-07-09 | Cg And Associates | Methods of delivery of cetyl myristoleate |
DE10005280A1 (de) * | 2000-02-07 | 2001-08-09 | Bayer Ag | Partikuläre Zusammensetzung, Verfahren zu ihrer Herstellung und deren Verwendung |
AU2001291721A1 (en) * | 2000-08-25 | 2002-03-04 | Merck Patent G.M.B.H | Powdered mannitol and mannitol-containing compositions |
US7163708B2 (en) * | 2001-06-19 | 2007-01-16 | E. I. Du Pont De Nemours And Company | Process for dry coating a food particle or encapsulating a frozen liquid particle |
WO2003045319A2 (en) * | 2001-11-21 | 2003-06-05 | Activbiotics, Inc. | Targeted therapeutics and uses thereof |
US7078399B2 (en) * | 2001-12-13 | 2006-07-18 | Activbiotics, Inc. | Sulfhydryl rifamycins and uses thereof |
US20040131730A1 (en) * | 2002-06-19 | 2004-07-08 | Dalziel Sean M. | Process for dry coating a food particle or encapsulating a frozen liquid particle |
ES2339003T3 (es) * | 2002-08-29 | 2010-05-14 | Activbiotics Pharma Llc | Rifalazil para tratar infecciones por clostridium difficile. |
US9060941B2 (en) * | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
TW200418485A (en) * | 2002-09-23 | 2004-10-01 | Activbiotics Inc | Rifalazil compositions and therapeutic regimens |
US8980870B2 (en) | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
EP1588708A4 (en) * | 2003-01-29 | 2006-03-01 | Takeda Pharmaceutical | METHOD FOR PRODUCING COATED PREPARATION |
US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
AU2004268531A1 (en) * | 2003-08-22 | 2005-03-10 | Activbiotics, Inc. | Rifamycin analogs and uses thereof |
US7820652B2 (en) * | 2003-09-24 | 2010-10-26 | Activbiotics Pharma, Llc | Regimen for the administration of rifamycin-class antibiotics |
WO2005030142A2 (en) | 2003-09-25 | 2005-04-07 | Activbiotics, Inc. | Rifalazil formulations |
US7220738B2 (en) * | 2003-12-10 | 2007-05-22 | Activbiotics, Inc. | Rifamycin analogs and uses thereof |
WO2005062882A2 (en) * | 2003-12-23 | 2005-07-14 | Activbiotics, Inc | Rifamycin analogs and uses thereof |
EP1642922B2 (en) * | 2004-09-30 | 2015-02-25 | Shin-Etsu Chemical Co., Ltd. | Cold water-soluble polymer particles and method for preparing |
CA2642761A1 (en) * | 2006-02-23 | 2007-08-30 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
AU2007235379A1 (en) * | 2006-04-06 | 2007-10-18 | Activbiotics Pharma Llc | Pharmaceutical compositions and uses thereof |
WO2007123113A1 (ja) * | 2006-04-17 | 2007-11-01 | Meiji Seika Kaisha, Ltd. | ホエープロテイン含有顆粒およびその製造方法 |
ZA200901075B (en) * | 2006-08-10 | 2010-05-26 | Takeda Pharmaceutical | Pharmaceutical composition |
WO2010005836A2 (en) * | 2008-07-07 | 2010-01-14 | Activbiotics Pharma, Llc | Use of rifalazil to treat colonic disorders |
GB0814953D0 (en) * | 2008-08-18 | 2008-09-24 | Unilever Plc | Improvements relating to nanodisperse compositions |
KR20110126747A (ko) * | 2009-03-06 | 2011-11-23 | 제노포트 인코포레이티드 | 고용량의 가바펜틴 프로드러그를 갖는 경구 투여 제형 |
JP2012533568A (ja) * | 2009-07-17 | 2012-12-27 | ケアフュージョン2200、インコーポレイテッド | 抗菌物質を包含する粒子 |
WO2012103116A1 (en) * | 2011-01-24 | 2012-08-02 | Activbiotics Pharma, Llc | Pulmonary administration of rifalazil and analogs thereof |
WO2015097090A1 (en) * | 2013-12-23 | 2015-07-02 | Laboratorios Del Dr. Esteve, S.A. | Oral pharmaceutical composition |
CN108261396B (zh) * | 2016-12-30 | 2021-12-24 | 北京化工大学 | 一种制粒方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4946585A (ja) * | 1972-09-11 | 1974-05-04 | ||
JPS5432176A (en) * | 1977-08-15 | 1979-03-09 | Sanyo Kokusaku Pulp Co Ltd | Granulating and drying method by fluidization |
JPS55129220A (en) * | 1980-02-08 | 1980-10-06 | Yamanouchi Pharmaceut Co Ltd | Composition for solid preparation containing hardly soluble medicinal component having rapid action and high bioavailability |
JPS6168133A (ja) * | 1984-09-08 | 1986-04-08 | Shinjiro Tsuji | 造粒方法 |
JPS63240934A (ja) * | 1987-03-28 | 1988-10-06 | Taisho Pharmaceut Co Ltd | 薬物の造粒法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2072037A (en) * | 1980-03-20 | 1981-09-30 | Standard Telephones Cables Ltd | Fluidising fine powder |
JPH06128147A (ja) * | 1992-10-20 | 1994-05-10 | Masayasu Sugihara | 水難溶性薬品の溶解性改善方法およびそれにより得られた薬品組成物 |
-
1993
- 1993-10-06 ES ES93922047T patent/ES2124794T3/es not_active Expired - Lifetime
- 1993-10-06 EP EP93922047A patent/EP0616841B1/en not_active Expired - Lifetime
- 1993-10-06 US US08/244,375 patent/US5547683A/en not_active Expired - Lifetime
- 1993-10-06 CA CA002124568A patent/CA2124568C/en not_active Expired - Fee Related
- 1993-10-06 DE DE69322764T patent/DE69322764T2/de not_active Expired - Lifetime
- 1993-10-06 KR KR1019940701971A patent/KR100294525B1/ko not_active IP Right Cessation
- 1993-10-06 JP JP50982594A patent/JP3492688B2/ja not_active Expired - Fee Related
- 1993-10-06 WO PCT/JP1993/001442 patent/WO1994008709A1/ja active IP Right Grant
- 1993-10-09 CN CN93118594A patent/CN1089234C/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4946585A (ja) * | 1972-09-11 | 1974-05-04 | ||
JPS5432176A (en) * | 1977-08-15 | 1979-03-09 | Sanyo Kokusaku Pulp Co Ltd | Granulating and drying method by fluidization |
JPS55129220A (en) * | 1980-02-08 | 1980-10-06 | Yamanouchi Pharmaceut Co Ltd | Composition for solid preparation containing hardly soluble medicinal component having rapid action and high bioavailability |
JPS6168133A (ja) * | 1984-09-08 | 1986-04-08 | Shinjiro Tsuji | 造粒方法 |
JPS63240934A (ja) * | 1987-03-28 | 1988-10-06 | Taisho Pharmaceut Co Ltd | 薬物の造粒法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0616841A4 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016106159A (ja) * | 1996-03-26 | 2016-06-16 | イーライ リリー アンド カンパニー | ベンゾチオフェン類、それを含む製剤、および方法 |
JP2015157865A (ja) * | 1996-03-26 | 2015-09-03 | イーライ リリー アンド カンパニー | ベンゾチオフェン類、それを含む製剤、および方法 |
JP2013166797A (ja) * | 1996-03-26 | 2013-08-29 | Eli Lilly & Co | ベンゾチオフェン類、それを含む製剤、および方法 |
JP2009019057A (ja) * | 1996-03-26 | 2009-01-29 | Eli Lilly & Co | ベンゾチオフェン類、それを含む製剤、および方法 |
JP2001509518A (ja) * | 1997-07-09 | 2001-07-24 | エラン ファーマシューティカル テクノロジーズ | セルロース系表面安定剤を用いたヒト免疫不全ウイルス(hiv)プロテアーゼ阻害剤のナノ結晶製剤及びそのような製剤の製造方法 |
JP2007246539A (ja) * | 1997-10-20 | 2007-09-27 | Dainippon Sumitomo Pharma Co Ltd | 速溶性医薬組成物 |
JP2003001091A (ja) * | 2001-06-26 | 2003-01-07 | Pauretsuku:Kk | 流動層造粒・コーティング方法 |
GB2402063B (en) * | 2003-03-06 | 2007-02-28 | Yamanouchi Pharma Co Ltd | Pharmaceutical composition for controlled release of active substances and the manufacturing method thereof |
GB2402063A (en) * | 2003-03-06 | 2004-12-01 | Yamanouchi Pharma Co Ltd | Medicinal composition for regulating release and process for producing the same |
WO2004078212A1 (ja) * | 2003-03-06 | 2004-09-16 | Yamanouchi Pharmaceutical Co., Ltd. | 放出制御用医薬組成物およびその製造方法 |
JP2010280707A (ja) * | 2003-07-11 | 2010-12-16 | F Hoffmann La Roche Ag | メシル酸サキナビル経口投与剤型 |
JP2007528865A (ja) * | 2003-07-17 | 2007-10-18 | エチファルム | 共沈活性物質含有粒子 |
JP4754485B2 (ja) * | 2003-07-17 | 2011-08-24 | エチファルム | 共沈活性物質含有粒子 |
JPWO2005065715A1 (ja) * | 2003-12-25 | 2007-07-26 | 武田薬品工業株式会社 | 造粒性改善方法 |
WO2005065715A1 (ja) * | 2003-12-25 | 2005-07-21 | Takeda Pharmaceutical Company Limited | 造粒性改善方法 |
WO2007126063A1 (ja) * | 2006-04-28 | 2007-11-08 | Lion Corporation | 造粒粒子、錠剤、及び造粒粒子の製造方法 |
JP2007314529A (ja) * | 2006-04-28 | 2007-12-06 | Lion Corp | 造粒粒子、錠剤、及び造粒粒子の製造方法 |
WO2011125500A1 (ja) * | 2010-03-31 | 2011-10-13 | エスエス製薬株式会社 | 難水溶性薬物含有微粒子造粒物の製造法 |
JP5825686B2 (ja) * | 2010-03-31 | 2015-12-02 | エスエス製薬株式会社 | 難水溶性薬物含有微粒子造粒物の製造法 |
JP2021075492A (ja) * | 2019-11-11 | 2021-05-20 | 花王株式会社 | 造粒物の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0616841A1 (en) | 1994-09-28 |
DE69322764D1 (de) | 1999-02-04 |
US5547683A (en) | 1996-08-20 |
CN1089234C (zh) | 2002-08-21 |
CA2124568A1 (en) | 1994-04-28 |
CA2124568C (en) | 2003-11-11 |
JP3492688B2 (ja) | 2004-02-03 |
KR100294525B1 (ko) | 2001-09-17 |
ES2124794T3 (es) | 1999-02-16 |
DE69322764T2 (de) | 1999-05-06 |
EP0616841A4 (en) | 1996-04-03 |
EP0616841B1 (en) | 1998-12-23 |
CN1091628A (zh) | 1994-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994008709A1 (en) | Production method for fine granulate | |
JP6479731B2 (ja) | 商業的ナノ粒子及びマイクロ粒子粉末の生産方法 | |
JP6460562B2 (ja) | 医薬コアシェル複合粉末、及びそれを作成するための方法 | |
JP2021100968A (ja) | 新たな医薬組成物 | |
ES2334991T3 (es) | Microparticulas de farmaco. | |
JP5484910B2 (ja) | レバプラザン含有の固体分散体及びその製造方法 | |
JP2017081983A (ja) | 商業的規模での封入ナノ粒子の製造 | |
TW201513896A (zh) | 醋酸阿比特龍配方 | |
NZ539277A (en) | Pharmaceutical product comprising a therapeutically active agent together with a pharmaceutical excipient for use with poorly water-soluble therapeutically active agents | |
JP2010047579A (ja) | セルロース系表面安定剤を用いたヒト免疫不全ウイルス(hiv)プロテアーゼ阻害剤のナノ結晶製剤及びそのような製剤の製造方法 | |
JP2023514767A (ja) | 医薬組成物 | |
JPH0717866A (ja) | 医薬組成物 | |
JP2019048854A (ja) | 商業的ナノ粒子及びマイクロ粒子粉末の生産方法 | |
WO1997033571A1 (fr) | Preparation d'ecadotril a microdispersion et liberation rapides | |
KR101730865B1 (ko) | 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법 | |
JP4754485B2 (ja) | 共沈活性物質含有粒子 | |
JP2010513324A (ja) | 医薬化合物および医薬組成物 | |
US20050215455A1 (en) | Surfactants in powdered form that can be used in tablets or gelatin capsules; preparation process and compositions containing them | |
JPWO2017209216A1 (ja) | 難溶性薬物の微粒子を含有する医薬組成物の製造方法 | |
WO1999020277A1 (fr) | Composition medicamenteuse a dissolution rapide | |
HB et al. | LIQUISOLID TECHNIQUE: A NOVEL APPROCH TO ENHANCE SOLUBILITY | |
JPH1179985A (ja) | 喘息治療用の粉末吸入剤 | |
WO1995011674A1 (fr) | Preparation granulaire | |
JP2007131587A (ja) | キノリノン誘導体を有効成分とする医薬組成物、及びその製造方法 | |
Doijad | Formulation, Solid State Characterization and Enhancement of Dissolution Rate of Olmesartan Medoxomil by Polyvinyl Alcohol-Polyethylene Glycol Graft Copolymer Based Nanoparticles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2124568 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08244375 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019940701971 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993922047 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1993922047 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993922047 Country of ref document: EP |